WallStSmart

AbbVie Inc (ABBV)vsAlignment Healthcare LLC (ALHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 1376% more annual revenue ($62.82B vs $4.26B). ABBV leads profitability with a 5.8% profit margin vs 0.5%. ABBV trades at a lower P/E of 124.8x. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

ALHC

Hold

45

out of 100

Grade: D+

Growth: 8.0Profit: 4.5Value: 4.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-78.8%)

Margin of Safety

-78.8%

Fair Value

$147.26

Current Price

$263.65

$116.39 premium

UndervaluedFair: $147.26Overvalued
ALHCUndervalued (+4.6%)

Margin of Safety

+4.6%

Fair Value

$21.37

Current Price

$18.29

$3.08 discount

UndervaluedFair: $21.37Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$447.53B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4210/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
32.2%10/10

Strong operational efficiency at 32.2%

Debt/EquityHealth
-11.0210/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$3.56B8/10

Generating 3.6B in free cash flow

ALHC1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
33.3%10/10

Revenue surging 33.3% year-over-year

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
124.8x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-46.2%2/10

Earnings declined 46.2%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

ALHC4 concerns · Avg: 3.5/10
Price/BookValuation
18.3x4/10

Trading at 18.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.5%3/10

0.5% margin — thin

Operating MarginProfitability
1.3%3/10

Operating margin of 1.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.

Bull Case : ALHC

The strongest argument for ALHC centers on Revenue Growth. Revenue growth of 33.3% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.

Bear Case : ALHC

The primary concerns for ALHC are Price/Book, EPS Growth, Profit Margin. A P/E of 206.0x leaves little room for execution misses. Debt-to-equity of 1.59 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABBV profiles as a value stock while ALHC is a hypergrowth play — different risk/reward profiles.

ALHC carries more volatility with a beta of 1.05 — expect wider price swings.

ALHC is growing revenue faster at 33.3% — sustainability is the question.

ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 45/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Alignment Healthcare LLC

HEALTHCARE · HEALTHCARE PLANS · USA

Alignment Healthcare, Inc. provides a consumer-centric platform that provides personalized healthcare to seniors in the United States. The company is headquartered in Orange, California.

Want to dig deeper into these stocks?